Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.
- First US patients enrolled and treated in PARADIGM trial
- Randomized controlled study compares DurAVR THV to commercial TAVRs
- Trial aims to enroll 1000 patients assessing mortality, stroke, hospitalisation
- CMS approval enabled rapid US site activation and patient enrolment
- DurAVR valve features patented biomimetic ADAPT tissue technology
First US Cases Mark Major Trial Milestone
Anteris Technologies (ASX:AVR) has achieved a significant clinical milestone by enrolling and treating the first patients in the United States as part of its global pivotal PARADIGM trial. The procedures, performed by Dr Azeem Latib at Montefiore Medical Center in New York, represent the US launch of this head-to-head study comparing Anteris’ DurAVR transcatheter heart valve (THV) against commercially available TAVR devices.
Dr Latib described the early procedural experience as "highly encouraging," highlighting the trial’s focus beyond conventional safety and hemodynamic metrics to also examine flow patterns and left ventricular recovery. This nuanced approach aims to generate evidence that could influence future standards of care for severe calcific aortic stenosis patients.
Trial Design and Recruitment Expansion
The PARADIGM trial is a prospective randomized controlled study targeting approximately 1000 patients in an 'All Comers Randomized Cohort.' Participants are randomized 1:1 to receive either the DurAVR THV or an approved commercial TAVR device. The primary composite endpoint includes all-cause mortality, all stroke, and cardiovascular hospitalisation at one year post procedure, assessing non-inferiority of DurAVR.
US patient enrolment was accelerated by recent CMS approval for Medicare reimbursement, which cleared a critical barrier for activating clinical sites. Wayne Paterson, Anteris’ CEO, noted the swift collaboration between the company and physician partners enabled first patient enrolments within a week of this approval, significantly expanding recruitment capacity in the US. This development builds on earlier capital raises and strategic investments that have underpinned trial progression and manufacturing scale-up efforts CMS approval accelerated enrolment $320M capital raise support.
Innovative Valve Technology at the Core
The DurAVR THV distinguishes itself with its biomimetic design, engineered to replicate the performance of a healthy human aortic valve. It is constructed from a single piece of Anteris’ patented ADAPT tissue, an FDA-cleared anti-calcification technology with over a decade of clinical use in more than 55,000 patients worldwide. The balloon-expandable valve is delivered via the ComASUR delivery system, combining to offer a restorative solution for structural heart disease.
As the trial progresses, the focus will be on how DurAVR’s unique design translates into clinical outcomes compared to established TAVRs, particularly regarding valve durability and impact on cardiac function.
Forward Steps and Investor Considerations
While the first US patient treatments mark a notable step forward, the PARADIGM trial remains ongoing with no interim clinical data disclosed yet. Investors should monitor enrollment progress and eventual outcome data releases to gauge DurAVR’s competitive positioning. The company’s forward-looking statements caution that risks and uncertainties remain, typical of pivotal medical device trials.
Bottom Line?
The successful US launch of the PARADIGM trial advances Anteris’ quest to validate DurAVR’s clinical value, but definitive results and broader market adoption remain on the horizon.
Questions in the middle?
- How will DurAVR’s biomimetic design impact long-term patient outcomes compared to existing TAVRs?
- What pace of enrollment can Anteris sustain across global sites to meet the 1000-patient target?
- When might interim or final clinical data from the PARADIGM trial be expected to influence regulatory and commercial decisions?